Xbrane Biopharma AB (XBRANE) Stock Forecast & Price Target

Q: What is SE:XBRANE’s average 12-month price target, according to analysts?

Based on analyst ratings, Xbrane Biopharma AB’s 12-month average price target is 0.45.

Q: What is SE:XBRANE’s upside potential, based on the analysts’ average price target?

Xbrane Biopharma AB has 59.56% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is Xbrane Biopharma AB a Buy, Sell or Hold?

Xbrane Biopharma AB has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

Q: What is Xbrane Biopharma AB’s share price target?

The average share price target for Xbrane Biopharma AB is 0.45. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst share price target is kr0.50 ,and the lowest forecast is kr0.50. The average share price target represents 59.56% Increase from the current price of kr0.28.

Q: What do analysts say about Xbrane Biopharma AB?

Xbrane Biopharma AB’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

Q: How can I buy shares of Xbrane Biopharma AB?

To buy shares of SE:XBRANE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Compare

7 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

XBRANE Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Xbrane

Biopharma AB

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

XBRANE Stock 12 Month Forecast

Average Price Target

kr0.45

▲(59.56% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Xbrane Biopharma AB in the last 3 months. The average price target is kr0.45 with a high forecast of kr0.50 and a low forecast of kr0.50. The average price target represents a 59.56% change from the last price of kr0.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"kr0","1":"kr1","-1":"-kr1","-0.5":"-kr0.5","0.5":"kr0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.499960908806535,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.4467576564,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr0.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.499960908806535,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.249,0.2683046852928104,0.28760937058562075,0.3069140558784311,0.3262187411712415,0.3455234264640519,0.3648281117568623,0.3841327970496727,0.40343748234248306,0.42274216763529343,0.4420468529281038,0.46135153822091424,0.4806562235137246,{"y":0.499960908806535,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.249,0.26421212741538463,0.2794242548307692,0.29463638224615385,0.30984850966153843,0.32506063707692306,0.3402727644923077,0.3554848919076923,0.3706970193230769,0.38590914673846155,0.40112127415384613,0.41633340156923077,0.4315455289846154,{"y":0.4467576564,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.249,0.2683046852928104,0.28760937058562075,0.3069140558784311,0.3262187411712415,0.3455234264640519,0.3648281117568623,0.3841327970496727,0.40343748234248306,0.42274216763529343,0.4420468529281038,0.46135153822091424,0.4806562235137246,{"y":0.499960908806535,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.183,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.138,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.183,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.226,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.172,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.16,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.174,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.157,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.205,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.195,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.195,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.236,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.249,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr0.50

Average Price Targetkr0.45

Lowest Price Targetkr0.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

kr0.5

Hold

78.57%

Upside

Reiterated

07/19/25

AI Generated ArticleAI Generated Article

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

kr0.5

Hold

78.57%

Upside

Reiterated

07/19/25

AI Generated ArticleAI Generated Article

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

XBRANE Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, XBRANE has received 0 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. XBRANE average Analyst price target in the past 3 months is 0.45.

Each month's total comprises the sum of three months' worth of ratings.

XBRANE Financial Forecast

XBRANE Earnings Forecast

Next quarter’s earnings estimate for XBRANE is kr0.11 with a range of kr0.11 to kr0.11. The previous quarter’s EPS was <kr0.01. XBRANE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.05% of the time in the same period. In the last calendar year XBRANE has Outperformed its overall industry.

XBRANE Sales Forecast

Next quarter’s sales forecast for XBRANE is kr321.37M with a range of kr321.37M to kr321.37M. The previous quarter’s sales results were kr93.24M. XBRANE beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 37.77% of the time in the same period. In the last calendar year XBRANE has Outperformed its overall industry.

XBRANE Stock Forecast FAQ

What is SE:XBRANE’s average 12-month price target, according to analysts?

Based on analyst ratings, Xbrane Biopharma AB’s 12-month average price target is 0.45.

What is SE:XBRANE’s upside potential, based on the analysts’ average price target?

Xbrane Biopharma AB has 59.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Xbrane Biopharma AB a Buy, Sell or Hold?

Xbrane Biopharma AB has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Xbrane Biopharma AB’s share price target?

The average share price target for Xbrane Biopharma AB is 0.45. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr0.50 ,and the lowest forecast is kr0.50. The average share price target represents 59.56% Increase from the current price of kr0.28.

What do analysts say about Xbrane Biopharma AB?

Xbrane Biopharma AB’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Xbrane Biopharma AB?

To buy shares of SE:XBRANE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Xbrane Biopharma AB (XBRANE) Stock Forecast & Price Target

XBRANE Analyst Ratings

XBRANE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

XBRANE Analyst Recommendation Trends

XBRANE Financial Forecast

XBRANE Earnings Forecast

XBRANE Sales Forecast

XBRANE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts